Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2010

NewGene to Provide NimbleGen Sequence Capture Services in the U.K.

  • NewGene has become a certified service provider (CSP) for NimbleGen Sequence Capture arrays in the U.K. It will provide services related to SeqCap EZ arrays with sequencing on the Genome Sequencer FLX System from 454 Life Sciences. In addition, it will process customer gDNA samples for genomic enrichment, using the complete NimbleGen Sequence Capture Array workflow optimized for 454 GS FLX Titanium Series sequencing.

    “The ability to couple NimbleGen Sequence Capture technology with our next-generation sequencing capabilities will provide significant scientific, technical, and economic benefits to our U.K, customers” says David Huntley, CEO at NewGene.

    NimbleGen Sequence Capture arrays enable users to produce targeted, sequencing-ready samples in the lab for use with next-generation sequencing instruments. Utilizing high-density, long-oligo NimbleGen arrays, either the whole human exome or the human genomic regions users specify are hybridized and eluted, ready for subsequent amplification and sequencing. The array-based process offers significant speed and scalability advantages over current PCR-based methods for targeted enrichment, according to Roche, NimbleGen's parent company.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »